Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003530811 | Liver | HCC | negative regulation of protein dephosphorylation | 24/7958 | 34/18723 | 8.62e-04 | 5.13e-03 | 24 |
GO:001821011 | Liver | HCC | peptidyl-threonine modification | 71/7958 | 125/18723 | 8.68e-04 | 5.14e-03 | 71 |
GO:001081122 | Liver | HCC | positive regulation of cell-substrate adhesion | 70/7958 | 123/18723 | 8.74e-04 | 5.18e-03 | 70 |
GO:000716021 | Liver | HCC | cell-matrix adhesion | 123/7958 | 233/18723 | 9.34e-04 | 5.47e-03 | 123 |
GO:009055912 | Liver | HCC | regulation of membrane permeability | 47/7958 | 78/18723 | 1.17e-03 | 6.54e-03 | 47 |
GO:00109217 | Liver | HCC | regulation of phosphatase activity | 50/7958 | 84/18723 | 1.22e-03 | 6.74e-03 | 50 |
GO:190204211 | Liver | HCC | negative regulation of extrinsic apoptotic signaling pathway via death domain receptors | 22/7958 | 31/18723 | 1.27e-03 | 6.92e-03 | 22 |
GO:00106772 | Liver | HCC | negative regulation of cellular carbohydrate metabolic process | 28/7958 | 42/18723 | 1.35e-03 | 7.26e-03 | 28 |
GO:00059781 | Liver | HCC | glycogen biosynthetic process | 29/7958 | 44/18723 | 1.46e-03 | 7.75e-03 | 29 |
GO:00092501 | Liver | HCC | glucan biosynthetic process | 29/7958 | 44/18723 | 1.46e-03 | 7.75e-03 | 29 |
GO:004690212 | Liver | HCC | regulation of mitochondrial membrane permeability | 39/7958 | 63/18723 | 1.47e-03 | 7.80e-03 | 39 |
GO:00712166 | Liver | HCC | cellular response to biotic stimulus | 128/7958 | 246/18723 | 1.53e-03 | 8.10e-03 | 128 |
GO:00325152 | Liver | HCC | negative regulation of phosphoprotein phosphatase activity | 19/7958 | 26/18723 | 1.57e-03 | 8.23e-03 | 19 |
GO:00459122 | Liver | HCC | negative regulation of carbohydrate metabolic process | 31/7958 | 48/18723 | 1.66e-03 | 8.71e-03 | 31 |
GO:001097511 | Liver | HCC | regulation of neuron projection development | 220/7958 | 445/18723 | 1.68e-03 | 8.78e-03 | 220 |
GO:00432551 | Liver | HCC | regulation of carbohydrate biosynthetic process | 56/7958 | 97/18723 | 1.75e-03 | 9.11e-03 | 56 |
GO:190102811 | Liver | HCC | regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway | 16/7958 | 21/18723 | 1.82e-03 | 9.37e-03 | 16 |
GO:000195421 | Liver | HCC | positive regulation of cell-matrix adhesion | 36/7958 | 58/18723 | 2.07e-03 | 1.04e-02 | 36 |
GO:004867511 | Liver | HCC | axon extension | 67/7958 | 120/18723 | 2.17e-03 | 1.09e-02 | 67 |
GO:199013811 | Liver | HCC | neuron projection extension | 92/7958 | 172/18723 | 2.31e-03 | 1.14e-02 | 92 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GSK3B | SNV | Missense_Mutation | | c.46N>T | p.Pro16Ser | p.P16S | P49841 | protein_coding | tolerated_low_confidence(0.36) | benign(0.003) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GSK3B | SNV | Missense_Mutation | novel | c.857C>G | p.Pro286Arg | p.P286R | P49841 | protein_coding | deleterious(0.03) | benign(0.162) | TCGA-C8-A8HR-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
GSK3B | insertion | Nonsense_Mutation | novel | c.1146_1147insGAAACCGGGAGGCGGAGGTTGCATTGAGCCGAGATTGCGCC | p.Asn383GlufsTer9 | p.N383Efs*9 | P49841 | protein_coding | | | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
GSK3B | insertion | In_Frame_Ins | novel | c.44_45insATCACAAGGAGAACTCTGTTTTGA | p.Lys15_Pro16insSerGlnGlyGluLeuCysPheGlu | p.K15_P16insSQGELCFE | P49841 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GSK3B | deletion | Frame_Shift_Del | novel | c.850delN | p.Met284Ter | p.M284* | P49841 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
GSK3B | SNV | Missense_Mutation | novel | c.259G>A | p.Val87Ile | p.V87I | P49841 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GSK3B | SNV | Missense_Mutation | novel | c.683N>A | p.Ile228Asn | p.I228N | P49841 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GSK3B | SNV | Missense_Mutation | rs72548709 | c.995N>A | p.Arg332His | p.R332H | P49841 | protein_coding | tolerated(0.07) | benign(0.003) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
GSK3B | SNV | Missense_Mutation | | c.713N>C | p.Ile238Thr | p.I238T | P49841 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
GSK3B | SNV | Missense_Mutation | | c.901T>C | p.Trp301Arg | p.W301R | P49841 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | PMID26161698-Compound-18 | | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | Neu-120 | | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | SOTRASTAURIN | SOTRASTAURIN | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | CYC-116 | CYC-116 | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | tideglusib | TIDEGLUSIB | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | inhibitor | 404859135 | | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | ALSTERPAULLONE | ALSTERPAULLONE | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | inhibitor | CHEMBL1200826 | LITHIUM CARBONATE | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | AMO-02 | | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | BETULINIC ACID | BETULINIC ACID | 19716700 |